JW Shinyak Corporation (KOSDAQ:067290)

South Korea · Delayed Price · Currency is KRW

3,265.00

-165.00 (-4.81%)

At close: Sep 4, 2026

Market Cap	182.42B +129.1%
Revenue (ttm)	81.04B -12.9%
Net Income	13.68B +208.1%
EPS	244.84 +294.9%
Shares Out	55.87M
PE Ratio	13.34
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	23,898,470
Open	3,440.00
Previous Close	3,430.00
Day's Range	3,095.00 - 3,445.00
52-Week Range	1,246.00 - 3,820.00
Beta	0.63
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 11, 2026

About JW Shinyak

JW Shinyak Corporation engages in the research, development, production, and sale of medicines and medical supplies in South Korea. It offers pharmaceutical products in the areas of dermatology, urology, pediatrics, otolaryngology, etc.; and cardiovascular, gastrointestinal, urinary, NSAIDs, antibiotics, anti-fungal, anti-viral, respiratory, antihistamines, steroid hormone, anti-obesity, and other products, as well as eye drops, and antitussives and expectorants. The company also develops prostate cancer treatment, liver cancer treatment, rheum... [Read more]

Industry Orthopedic, Prosthetic, and Surgical Appliances and Supplies

Founded 1981

Employees 183

Stock Exchange KOSDAQ

Ticker Symbol 067290

Full Company Profile

Financial Performance

In 2025, JW Shinyak's revenue was 81.04 billion, a decrease of -12.87% compared to the previous year's 93.01 billion. Earnings were 13.68 billion, an increase of 169.24%.

Financial Statements